Cancidas

   
Google
 
Web NewDrugInformation.com

Cancidas


Drug - Cancidas
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; IV (INFUSION)
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Caspofungin Acetate
Multiple ingredients are in alphabetical order.

Strength - 70MG/VIAL
The potency of the active ingredient(s), Caspofungin Acetate. May repeat for multiple part products.

Applicant - MERCK RES
The firm name holding legal responsibility for Cancidas. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 021227
The FDA assigned number to Cancidas. Format is nnnnnn.

Product Number - 002
The FDA assigned number to identify Cancidas. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jan 26, 2001
The date Cancidas was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Cancidas. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Cancidas is in. Format is RX, OTC, DISCN.

Applicant Full Name - Merck Research Laboratories
The full name of the firm holding legal responsibility for the new application of Cancidas.

Cancidas